Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosutinib and Inotuzumab Ozogamicin in Ph+ ALL and CML-LBC
NCT02311998Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2015
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bosutinib, inotuzumab ozogamicin in acute lymphoblastic leukemia (ALL), Chronic Myeloid Leukemia, Lymphoid Blast Phase (CML-LBP), sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2015; status: completed.
02
Drugs
bosutinibinotuzumab ozogamicin
03
Conditions
acute lymphoblastic leukemia (ALL)Chronic Myeloid Leukemia, Lymphoid Blast Phase (CML-LBP)
Beyond the preview
Go deeper on NCT02311998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02311998.